Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study")
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- Acronyms ProDERM
- Sponsors Octapharma
- 06 Apr 2017 Status changed from not yet recruiting to recruiting.
- 08 Aug 2016 Planned initiation date changed from 1 Sep 2016 to 1 Dec 2016.
- 12 Apr 2016 New trial record